Infinity Pharmaceuticals Buy Hold or Sell Recommendation

INFI -- USA Stock  

USD 1.74  0.10  5.43%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Infinity Pharmaceuticals is 'Cautious Hold'. Macroaxis provides Infinity Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Infinity Pharmaceuticals positions. The advice algorithm takes into account all of Infinity Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from Infinity Pharmaceuticals buy-and-hold prospective. Please also check Infinity Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.

Time Horizon

Risk Tolerance

Execute Advice

Infinity Pharmaceuticals Current Recommendation

Cautious Hold

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

For the selected time horizon Infinity Pharmaceuticals has a mean deviation of 2.88, semi deviation of 0.0, standard deviation of 3.74, variance of 13.97, downside variance of 0.0 and semi variance of 0.0
We provide buy, hold, or sell suggestion to complement the regular expert consensus on Infinity Pharmaceuticals. Our dynamic recommendation engine utilizes multi - dimensional algorithm to analyze the organization potential to grow using all technical and fundamental data available at the time. To make sure Infinity Pharmaceuticals is not overpriced, please check out all Infinity Pharmaceuticals fundamentals including its Shares Owned by Institutions, Net Income, Earnings Per Share, as well as the relationship between Price to Sales and Current Ratio . Please also validate Infinity Pharmaceuticals Price to Earning to confirm your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.

Returns Distribution Density

Mean Return0.54Value At Risk5.49
Potential Upside4.86Standard Deviation3.74
 Return Density 

Institutional Investors

Security TypeSharesValue
Bvf IncCommon Shares9.8 M20.5 M
Fmr LlcCommon Shares3.6 M7.5 M
Vanguard Group IncCommon Shares2 M4.2 M
Ghost Tree Capital LlcCommon Shares1.8 M3.7 M
Wellington Management Group LlpCommon Shares1.5 M3.2 M
Platinum Investment Management LtdCommon Shares1.3 M2.7 M
Blackrock IncCommon Shares951.9 K2 M

Infinity Pharmaceuticals Greeks

Alpha over DOW
Beta against DOW=0.00
Overall volatility
Information ratio =0.14

Infinity Pharmaceuticals Volatility Alert

Infinity Pharmaceuticals exhibits very low volatility with skewness of -0.01 and kurtosis of -0.26. However, we advise investors to further study Infinity Pharmaceuticals technical indicators to make sure all market info is available and is reliable.
 Better Than Average     
 Worse Than Average Compare Infinity Pharmaceuticals to competition

Infinity Pharmaceuticals Fundamental Vs Peers

FundamentalsInfinity PharmaceuticalsPeer Average
Return On Equity(68.47) % (15.17) %
Return On Asset(28.88) % (15.64) %
Operating Margin(591.43) % (10.91) %
Current Valuation57.6 M152.14 B
Shares Outstanding56.07 M1.43 B
Shares Owned by Insiders3.33 % 6.91 %
Shares Owned by Institutions55.65 % 18.37 %
Number of Shares Shorted1.7 M3.24 M
Price to Earning1.63 times40.69 times
Price to Book1.96 times14.44 times
Price to Sales17.19 times17.81 times
Revenue6 M9.85 B
Gross Profit6 M21.75 B
EBITDA(34.4 M)1.41 B
Net Income(40.81 M)517.71 M
Cash and Equivalents47.81 M3.89 B
Cash per Share0.85 times5.17 times
Debt to Equity12.50 % 0.72 %
Current Ratio10.80 times3.30 times
Book Value Per Share0.94 times13.64 times
Cash Flow from Operations(28.79 M)1.25 B
Short Ratio4.19 times2.09 times
Earnings Per Share0.83 times2.30 times
Price to Earnings To Growth0.03 times1.22 times
Number of Employees2210.67 K
Market Capitalization103.17 M29.78 B
Total Asset288.82 M126.86 B
Retained Earnings(595.59 M)38.24 B
Working Capital184.64 M3.58 B
Current Asset254.7 M36.8 B
Current Liabilities70.06 M33.34 B
Z Score-2.8708.73
   Acquisition by Michael Venuti of 4000 shares of Infinity Pharmaceuticals subject to Rule 16b-3 [view details]

Infinity Pharmaceuticals Alerts

Trading Alerts and Improvement Suggestions
Infinity Pharmaceuticals generates negative expected return over the last 30 days
Infinity Pharmaceuticals may become a speculative penny stock
Infinity Pharmaceuticals has high historical volatility and very poor performance
Infinity Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Infinity Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported previous year revenue of 6 M. Net Loss for the year was (40.81 M) with profit before overhead, payroll, taxes, and interest of 6 M.
INFINITY PHARMACE currently holds about 47.81 M in cash with (28.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85.
Roughly 56.0% of the company shares are owned by institutional investors
Latest headline from Influential Analyst Rating Changes Infinity Pharmaceuticals, Inc. , Nxstage Medical, Inc.

Did You Try This Idea?

Run Utilities Thematic Idea Now
Utilities Idea
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. Utilities theme has 30 constituents.
View All  Next Launch Utilities
Please also check Infinity Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.